Elritercept
Near Add Your Location
Accepting patients
KER-050
A Phase 2, Open-Label, Ascending Dose Study of KER-050 for the Treatment of Anemia in Patients With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS)
- Growth Factor
- Phase 2
- Has results
Accepting patients
RENEW
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Elritercept (KER-050) for the Treatment of Transfusion-Dependent Anemia in Adult Participants with Very Low-, Low-, or Intermediate-Risk Myelodysplastic Syndromes (MDS) (RENEW)
- Activin Receptor IIA Inhibitor
- Closed Label (Masked)
- Placebo
- Phase 3